Fadahossein Maleki said the plan had been formally registered in parliament, while the Supreme National Security Council also wanted to examine it.
Maleki, a member of Iran parliament’s national security and foreign policy committee, also said various proposals had been discussed in the committee and in other parliamentary meetings on Hormuz.
F. Hoffmann-La Roche AG said its group sales reached CHF 14.7 billion in the first quarter of 2026, rising 6% at constant exchange rates (CER) but falling 5% in CHF.
Sales in the pharmaceuticals division came in at CHF 11.5 billion, rising 7% at CER but declining 4% in CHF, driven by demand for key medicines including Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus. Diagnostics sales stood at CHF 3.3 billion, increasing 3% at CER but falling 7% in CHF, as growth in core lab and pathology solutions offset pricing pressure in China.
"We delivered a strong start to the year, achieving 6% Group sales growth at constant exchange rates," Chief Executive Thomas Schinecker said. "Our pipeline continued to advance in areas where patients face significant unmet need, including multiple sclerosis, obesity and a severe autoimmune disease that can lead to kidney failure," he added, noting the company confirmed its full-year outlook.
https://breakingthenews.net/Article/Roche-Q1-sales-fall-5-to-CHF-14.7B/66130194
Sanofi SA revealed on Thursday that its net sales in the first quarter of the fiscal year 2026 saw an annual rise of 6.2% and 13.6% at the constant exchange rate (CER), to reach €10.5 billion.
The company's net income, calculated according to the International Financial Reporting Standards (IFRS), came in at €1.6 billion, and its IFRS earnings per share (EPS) at €1.34, down 11.8% on a yearly basis. Meanwhile, its business net income rose by 2.4%, or 11.1% at CER, to €2.3 billion, and its business EPS jumped by 5% and14% at CER, to €1.88. In the first quarter, Sanofi's gross profit rose 6.1% and 14.4% at CER, to €8.2 billion.
"We had a strong start to 2026 with double-digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions ... We obtained five regulatory approvals, all in immunology, achieved one positive phase 3 study readout for venglustat in rare diseases, and reported encouraging phase 2 data for lunsekimig in respiratory diseases," Interim CEO Olivier Charmeil said.
https://breakingthenews.net/Article/Sanofi's-Q1-net-sales-up-by-6.2-to-euro10.5-billion/66130413
Mobia Medical, which sells a nerve stimulation device for chronic ischemic stroke, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Mobia's Vivistim Paired Vagus Nerve Stimulation System is the first and only clinically-validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The system includes an implanted pulse generator and lead that deliver stimulation during functional movement in order to increase neuroplasticity and durably restore motor function. Management estimates that there are over four million chronic ischemic stroke survivors, of which one million have the health, cognition, and motivation to participate in post-stroke therapy, representing a $30 billion opportunity based on the system's price.
The Austin, TX-based company was founded in 2007 and booked $32 million in revenue for the 12 months ended December 31, 2025. It plans to list under the symbol MOBI. Mobia Medical filed confidentially on January 21, 2026. BofA Securities, J.P. Morgan, and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
GMR Solutions, which is leading provider of emergency medical services and alternate-site care in the US, filed on Friday with the SEC to raise up to what we estimate could be $1.0 billion in an initial public offering.
Formed in 2018 through the merger of Air Medical Group Holdings and American Medical Response, GMR Solutions is a provider of emergency medical services and out-of-hospital care in the United States and internationally. The company delivers on-site clinical care through trained medical teams and coordinates patient transport via air and ground ambulance when higher levels of care are required, or directs non-emergent patients to lower-acuity settings. Its operations span a broad network of urban and rural communities, functioning as an entry point into the healthcare system and supporting care delivery across a range of emergency and non-emergency situations.
The Lewisville, TX-based company was founded in 2018 and booked $5.7 billion in revenue for the 12 months ended December 31, 2025. It plans to list on the NYSE under the symbol GMRS. GMR Solutions filed confidentially on October 28, 2025. J.P. Morgan, KKR, BofA Securities, Barclays, Goldman Sachs, Citi, Evercore ISI, Morgan Stanley, and UBS Investment Bank are the joint bookrunners on the deal.
National Healthcare Properties, a healthcare REIT focused on outpatient medical and senior housing properties, raised $462 million by offering 38.5 million shares at $12, below the $13 to $16 range.
National Healthcare Properties is a self-managed real estate investment trust that owns a portfolio of senior housing and healthcare properties across 29 states. The company operates through two primary segments: Senior Housing Operating Properties, which consists of assisted living and memory care communities operated under RIDEA structures, and Outpatient Medical Facilities, which comprises medical office buildings largely affiliated with or adjacent to hospital systems. The SHOP portfolio is managed through third-party operators, while the OMF segment transitioned to in-house property management in 2025. Top MSAs include Philadelphia, Orlando, and Miami. The REIT was previously managed by AR Global, prior to its 2024 internalization. The company plans to pay a quarterly distribution.
The New York, NY-based company will trade on the Nasdaq under the symbol NHP. Wells Fargo Securities, Morgan Stanley, BMO Capital Markets, Goldman Sachs, RBC Capital Markets, Baird, Capital One Securities, Fifth Third Securities, Huntington Investment, and KeyBanc Capital Markets acted as joint bookrunners on the deal.
Last month's Iranian drone strike on Prince Sultan Air Base in Saudi Arabia appears to have inflicted a costly toll on U.S. forces in the region. The attack destroyed a U.S. Air Force E-3 Sentry Airborne Warning and Control System aircraft and damaged multiple KC-135 refueling tankers, highlighting a major gap in U.S. air defenses against cheap attack drones.
Nearly a month after the drone strike on Prince Sultan Air Base, and following multiple reports that Ukrainian drone forces had been shifted into the region, Reuters confirmed Wednesday morning that the U.S. has deployed Ukrainian counter-drone technology to defend against Iranian-developed Shahed drones.
At the center of this new security effort to fortify the airspace above Prince Sultan Air Base against low-cost Iranian one-way attack drones is Sky Map, a Ukrainian command-and-control platform used to detect incoming drones. The coordinated response to Shaheds is the use of interceptor drones.
"There have been longstanding gaps in U.S. air and missile defense coverage around the world," said Timothy Walton, a senior fellow at the Washington-based Hudson Institute think tank. "This has been well understood. However, it hasn't been addressed."
Ukrainian drone experts reportedly traveled to the base in recent weeks to train U.S. personnel on Sky Map and the use of interceptor drones.
Sky Fortress, the Ukrainian company behind Sky Map, has been active extensively in the Eastern European theater, with more than 10,000 acoustic sensors deployed to detect Russian drone attacks.
The bigger story here is that Ukraine is emerging as a major dealer of the latest low-cost weapon technology forged through four years of war with Russia:
Zelensky Goes Full "Lord Of War" As Ukraine Pitches Battle-Tested War Robots To Highest Bidder
Zelensky's Interceptor Drones Deployed Across Eurasia, Now Shooting Down Iranian Shaheds
Our assessment is that, if we had to get granular, passive acoustic counter-drone detection will become a standard layer of air defense for U.S. military bases, data centers, critical U.S. infrastructure, and government buildings in the years ahead. As cheap attack drones proliferate, adopting passive acoustic sensing systems for early warning will help close the air-defense gap against them. Just wait until these early-detection systems are paired with 'micro' sentry guns and fully automated AI kill chains.
